Hostname: page-component-848d4c4894-hfldf Total loading time: 0 Render date: 2024-06-02T23:52:46.089Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychostimulant Treatment of Stroke and Brain Injury

Published online by Cambridge University Press:  07 November 2014

Steven R. Flanagan
Get access Rights & Permissions [Opens in a new window]

Abstract

Psychopharmacology is rapidly becoming an adjuvant treatment to traditional rehabilitation strategies for patients with stroke or brain injury because it helps to facilitate recovery in a time-efficient manner. Norepinephrine, dopamine, acetylcholine, and serotonin appear to play important roles in recovery from stroke or brain injury. Animal models have shown that blockade of these neurotransmitters inhibits recovery, whereas recovery is promoted by drugs that promote norepinephrine, dopamine, acetylcholine, and serotonin activity. Preliminary evidence from human trials supports these finding. Further study is needed, but expanded use of pharmacologic agents for stroke and brain-injured patients appears imminent.

Type
Feature Articles
Information
CNS Spectrums , Volume 5 , Issue 3: Neurologic and Psychiatric Sequelae of Stroke , March 2000 , pp. 59 - 69
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Aston-Jones, G, Chiang, C, Alexinsky, T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggesting a role in vigilance. Prog Brain Res. 1991;88:501–520.Google Scholar
2.Carli, M, Robbins, TW, Evenden, JL, et al.Effects of lesions to ascending noradrenergic neurons on performance on a 5-choice serial reaction task in rats: implications for theories of dorsal noradrenergic bundle function based on selective attention and dorsal. Behav Brain Res. 1983;9:361–380.Google Scholar
3.Feeney, DM, Gonzalez, A, Law, WA. Amphetamine, haloperidol and experience interact to affect the rate of recovery after motor cortex - injury. Science. 1982;217:885–857.Google Scholar
4.Hovda, DA, Feeney, DM. Amphetamine with experience promotes recovery of locomoter function after unilateral frontal cortex-injury in the cut. Brain Res. 1984;298:358–361.Google Scholar
5.Kline, AE, Chen, MJ, Tso-Olivas, DY, Feeney, DM. Methylphenidate treatment following ablation-induced hemiplegia in rat: experience during drug action alters effects on recovery of function. Pharmacol Biochem Behav. 1994;48:773–779.Google Scholar
6.Boyeson, MG, Feeney, DM. Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury. Pharmacol Biochem Behav. 1990;35:497–501.CrossRefGoogle ScholarPubMed
7.Goldstein, LB, Davis, JN. Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat. Brain Res. 1990;508:305–309.CrossRefGoogle ScholarPubMed
8.Feeney, DM, Westerberg, VS. Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychol. 1990;44:233–252.Google Scholar
9.Stephens, J, Goldberg, G, Demopoulos, JT. Clonidine reinstates deficits following recovery from sensorimotor cortex lesions in rats. Arch Phys Med Rehabil. 1986;67:666–667.Google Scholar
10.Lipper, S, Tachman, MM. Treatment of chronic post-traumatic organic brain syndrome with dextroamphetamine: first reported case. J Nerv Ment Dis. 1976;162:366–371.Google Scholar
11.Evans, RW, Gualtieri, CT, Paterson, D. Treatment of chronic closed head injury with psychostimulant drugs. A controlled case study and an appropraite evaluation of procedure. J Nerv Ment Dis. 1987;175:106–110.Google Scholar
12.Gualtieri, CT, Evans, RW. Stimulant treatment for the neuro-behavioral sequelae of traumatic brain injury. Brain Inj. 1988;2:273–290.Google Scholar
13.Hornstein, A, Lennihau, L, Seliger, G, Lichtman, S, Schroeder, K. Amphetamine in recovery from brain injury. Brain Inj. 1996;10:145–148.Google Scholar
14.Kaelin, DL, Cifu, DX, Matthies, B. Methylphenidate effect on attention deficit in the acutely brain injured adults. Arch Phys Med Rehabil. 1996;77:6–9.Google Scholar
15.Plenger, PM, Dixon, CE, Castillo, RM, Frankowski, RF, Yablon, SA, Levin, HS. Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury. A preliminary double blind placebo controlled study. Arch Phys Med Rehabil. 1996;77:536–540.Google Scholar
16.Mahalick, DM, Carmel, PW, Greenberg, JP, et al.Psychopharmacologic treatment of acquired attention disorders in children with brain injury. Pediatr Neurosurg. 1988;29:121–126.Google Scholar
17.Whyte, J, Hart, T, Schuster, K, Fleming, M, Polansky, M, Coslett, HB. Effects of methylphenidate on attentional function after traumatic brain injury. A randomized placebo-controlled trial. Am J Phys Med Rehabil. 1997;76:440–450.Google Scholar
18.Walker-Batson, D, Smith, P, Curtis, S, Unwein, H, Greenlee, R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke. 1995;26:2254–2259.Google Scholar
19.Grade, C, Redford, B, Chrostowski, J, Toussaint, L, Blackwell, B. Methylphenidate in early post-stroke recovery: a double blind, placebo-controlled study. Arch Phys Med Rehabil. 1998;79:1047–1050.Google Scholar
20.Goldstein, LB. Common drugs may influence motor recovery after stroke. The Sygen in acute stroke study investigators. Neurology. 1995;45:865–871.Google Scholar
21.Goldstein, LB, Davis, JN. Physician prescribing patterns after ischemic stroke. Neurology. 1988;38:1806–1809.Google Scholar
22.Goldstein, LB. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury. J Neurol Neurosurg Psychiatry. 1995;58:753–755.Google Scholar
23.Feeney, DM. Pharmacology modulation of recovery after brain injury: a recommendation of diaschisis. Journal of Neurological Rehabilitation. 1991;5:113–128.Google Scholar
24.Dietrich, WP, Alonson, O, Buto, R, Watson, BD, Loor, Y, Ginsberg, MD. Influence of amphetamine treatment on somatosensory function of the normal infarcted rat brain. Stroke. 1990;21(suppl):47–50.Google Scholar
25.Goldstein, LB. Pharmacologic of recovery after stroke. Stroke. 1990;21(suppl):139–141.Google Scholar
26.Brown, TH, Chapman, PF, Kairiss, EN, Keenan, CL. Long-term synaptic potentiation. Science. 1988;242:724–728.Google Scholar
27.Dunwiddie, TV, Roberson, NL, Worth, T. Modulation of long term potentiation. Effects of adrenergic and neuroleptic drugs. Pharmacol Biochem Behav. 1982;17:1257–1264.Google Scholar
28.Gendelmacher, DS. Enhancing recovery from ischemic stroke. Neurosurg Clin N Am. 1997;8:245–251.Google Scholar
29.Morris, PL, Raphael, B, Robinson, RG. Clinical depression is associated with impaired recovery from stroke. Med J Aust. 1992;157:239–242.Google Scholar
30.Lingam, VR, Lazarus, LW, Groves, L, Oh, SH. Methylphenidate in treating poststroke depression. J Clin Psychiatry. 1998;49:151–153.Google Scholar
31.Lazarus, LW, Winemiller, DR, Lingam, VR, et al.Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry. 1992;53:447–449.Google Scholar
32.Johnson, ML, Roberts, MD, Ross, AR, Witten, CM. Methylphenidate in stroke patients with depression. Am J Phys Med Rehabil. 1992;71:239–241.Google Scholar
33.Cooper, JR, Bloom, FE, Roth, RH. The Biochemical Basis of Neuropharmacology, 7th ed. New York, NY: Oxford University Press; 1996:293–351.Google Scholar
34.Homykiewicz, O. Parkinson's disease: from brain homogenate to treatment. Fed Proc. 1973;32:183–190.Google Scholar
35.Crow, TJ, Johnstone, EC, Longden, AJ, Owen, F. Dopaminergic mechanism in schizophrenia: the antipsychotic effect and the disease process. Life Sci. 1978;23:563–568.Google Scholar
36.Stevens, JR. An anatomy of schizophrenia? Arch Gen Psychiatry. 1973;29:177–189.Google Scholar
37.Stevens, JR, Livermore, A Jr. Kindling of the mesolimbic dopamine system: animal model of psychosis. Neurology. 1978;28:36–46.Google Scholar
38.Gianutsos, G, Chute, S, Dunn, JA. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985;110:357–361.Google Scholar
39.Allen, RM. Role of amantadine in the management of neuorleptic-induced extrapyramidal syndromes: overview and pharmacology. Clin Neuropharmacol. 1983;6(suppl):564–573.Google Scholar
40.Feeney, DM, Westerberg, VS. Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychol. 1990;44:233–252.Google Scholar
41.Hovda, DA, Sutton, RL, Feeney, DM. Amphetamine-induced recovery of visual cliff performance after bilateral visual cortex ablation in cats: measurements of depth perception thresholds. Behav Neurosci. 1989;103:574–585.Google Scholar
42.Hovda, DA, Sutton, RL, Feeney, DM. Recovery of tactile placing after visual cortex ablation in cats: a behavioral and metabolic study of diaschisis. Exp Neurol. 1987;97:391–402.Google Scholar
43.Hovda, DA, Feeney, DM. Haloperidol blocks amphetamine induced recovery of binocular depth perception after bilateral visual cortex ablation in cats. Proc West Pharmacol Soc. 1987;28:209–211.Google Scholar
44.Chierichetti, SM, Ferrari, P, Sala, P, et al.Effect of amantadine in mental states of elderly patients: a double-blind comparison with placebo. Curr Ther Res. 1977;22:158–165.Google Scholar
45.Botez, MI, Young, SN, Botez, T, et al.Treatment of Friedreich's ataxia with amantadine. Neurology. 1989;39:749.Google Scholar
46.Perterson, PL, Saas, J, Nigro, MA. The treatment of Friedreich's ataxia with amantadine hydrochloride. Neurology. 1988;38:1478–1480.Google Scholar
47.Murray, TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci. 1985;12:251–254.Google Scholar
48.Rosenberg, GA, Appenzeller, O. Amantadine, fatigue and multiple sclerosis. Arch Neurol. 1988;45:1104–1106.Google Scholar
49.Dunn, MG. Postpolio fatigue treated with amantadine. Arch Neurol. 1991;48:570.Google Scholar
50.Haig, AJ, Ruess, JM. Recovery from vegetative state of six months' duration associated with sinemet (levodopa/carbidopa). Arch Phys Med Rehabil. 1990;71:1081–1083.Google Scholar
51.Zafonte, RD, Watanabe, T, Mann, NR. Amantadine: a potential treatment for the minimally conscious state. Brain Inj. 1998;12:617–621.Google Scholar
52.Lai, S, Merbits, C, Grip, J. Modification of function in head-injured patients with sinemet. Brain Inj. 1990;2:225–233.Google Scholar
53.Nickels, JL, Schneider, WN, Dombovy, ML, Wong, TM. Clinical use of amantadine in brain injury rehabilitation. Brain Inj. 1994;8:709–718.Google Scholar
54.Edby, K, Larrson, J, Eek, M, Von Wendt, L, Ostergard, B. Amantadine treatment of a patient with anoxic brain injury. Child's Nerv Syst. 1995;11:607–609.Google Scholar
55.Kraus, MF, Maki, PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry. 1997;9:222–230.Google Scholar
56.McDowell, S, Whyte, J, D'Esposito, M. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain. 1998;121:1155–1164.Google Scholar
57.Gualtieri, T, Chandler, M, Coons, TB, Brown, LT. Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol. 1989;12:258–270.CrossRefGoogle ScholarPubMed
58.Van Reekum, R, Bayley, M, Garner, S, et al.N of 1 study: amantadine for the amotivation syndrome in patient with traumatic brain injury. Brain Inj. 1995;9:49–53.Google Scholar
59.Suitsu, N. A computer assisted EEG study on psychotropic properties of antiparkinsons drugs. Seishin Shinkeigaku Zasshi. 1992;94:238–262.Google Scholar
60.Corwin, JV, Burcham, KJ, Hix, GI. Apomorphine produces an acute dose-dependent therapeutic effect on neglect produced by unilateral destruction of the posterior parietal cortex. Behav Brain Res. 1996;79:41–49.Google Scholar
61.Kalra, L, Perez, I, Gupta, S, Wittink, M. The influence of visual neglect on stroke rehabilitation. Stroke. 1997;28:1386–1391.Google Scholar
62.Inversen, SD. Behavioural effects of manipulation of basal ganglia neurotransmitters. Ciba Found Symp. 1984;107:183–200.Google Scholar
63.Vargo, JM, Bromberg, BB, Best, PJ, Corwin, JV, Marshall, JF. D-1 class dopamine receptor involvement in the behavioral recovery from prefrontal cortical injury. Behav Brain Res. 1995;72:39–48.Google Scholar
64.Fleet, WS, Valenstein, E, Watson, RJ, Heilman, KM. Dopamine agonist therapy for neglect in humans. Neurology. 1987;37:1765–1770.CrossRefGoogle ScholarPubMed
65.Geminiani, G, Bottini, G, Sterzi, R. Dopaminergic stimulation in unilateral neglect. J Neurol Neurosurg Psychiatry. 1998;65:344–347.Google Scholar
66.Hurford, P, Stringer, AY, Jann, B. Neuropharmacological treatment of hemineglect: a case report comparing bromocriptine and methylphenidate. Arch Phys Med Rehabil. 1998;79:346–349.CrossRefGoogle ScholarPubMed
67.Gurjic, Z, Mapstone, M, Gitelman, DR, et al.Dopamine agonists reorient exploration away from the neglected hemisphere. Neurology. 1998;51:1395–1398.Google Scholar
68.Barrett, AM, Crucian, GP, Schwartz, RL, Heilman, KM. Adverse effect of dopamine agonist therapy in a patient with motor-intentional neglect. Arch Phys Med Rehabil. 1999;80:600–603.Google Scholar
69.Albert, ML, Bachman, DL, Morgan, A, Helm-Estabrooks, N. Pharmocotherapy for aphasia. Neurology. 1988;38:877–879.Google Scholar
70.Gupta, SR, Micoch, AG. Bromocriptine treatment of nonfluent aphasia. Arch Phys Med Rehabil. 1992;73:373–376.Google Scholar
71.Sabe, L, Leiguarda, R, Starkstein, SE. An open-label trial of bromocriptine in nonfluent aphasia. Neurology. 1992;42:1636–1638.Google Scholar
72.Small, SL. Pharmacotherapy of aphasia: a critical review. Stroke. 199;25:1282–1289.CrossRefGoogle Scholar
73.MacLennan, DL, Nicholas, LE, Morley, GK, Brookshire, RH. The effects of bromocriptine on speech and language function in a man with transcortical aphasia. Clinical Aphasiology. 1991;21:145–155.Google Scholar
74.Ozeren, A, Sarica, Y, Mavi, H, Demirkiran, M. Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. Acta Neurol Belg. 1995;95:235–238.Google ScholarPubMed
75.Lindvall, O, Bjorkland, A, Divac, I. Organization of catecholamine neurons projecting to frontal cortex in rat. Brain Res. 1978;142:1–24.Google Scholar
76.Robertson, A, Mogenson, JG. Evidence for a role for dopamine in self stimulation of the nucleus accumbens of the rat. Can J Psychol. 1978;32:67–76.Google Scholar
77.Bozarth, MS, Wise, RA. Involvement of the ventral tegmental dopamine system in opioid and psychomotor stimulant reinforcement. Life Sci. 1981;28:551–555.Google Scholar
78.Bozarth, MS, Wise, RA. Heroin reward is dependent on a dopaminergic substrate. Life Sci. 1981;29:1881–1886.Google Scholar
79.Yoshida, M, Yokoo, H, Mizoguchi, K, et al.Eating and drinking cause increased dopamine release in the nucleus accumbens and ventral tegmental area in the rat: measurement by in vivo microdialysis. Neurosci Lett. 1992;139:73–76.Google Scholar
80.Pfaus, JG, Phillips, AG. Role of dopamine in anticipatory and consummatory aspects of sexual behaviour in the male rat. Behav Neurosci. 1991;105:727–743.Google Scholar
81.Marshall, JF, Turner, BH, Teitelbaum, P. Sensory neglect produced by lateral hypothalamic damage. Science. 1971;174:523–525.Google Scholar
82.Ungerstedt, U. Is interruption of the nigrostriatal dopamine system producing in the lateral hypothalamic syndrome. Acta Physiol Scand. 1970;80:35A–36A.Google Scholar
83.Ungerstedt, U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand Suppl. 1971;367:95–122.Google Scholar
84.Marshall, JF, Richardson, JS, Teitelbaum, P. Nigrostriatal bundle damage and the lateral hypothalamic syndrome. J Comp Physiol Psychol. 1974;87:808–830.Google Scholar
85.Ross, ED, Stewart, M. Akinetic mutism from hypothalamic damage. Successful treatment with dopaminergic agonists. Neurology. 1981;31:1435–1439.Google Scholar
86.Barrett, K. Treating organic abulia with bromocriptine and lisuride: four case studies. J Neurol Neurosurg Psychiatry. 1991;54:718–721.CrossRefGoogle ScholarPubMed
87.Nichels, JL, Schneider, WN, Dombovy, ML, Wong, TM. Clinical use of amantadine in brain injury rehabilitation. Brain Inj. 1994;8:709–718.Google Scholar
88.Powell, JH, al-Adawi, S, Morgan, J, Greenwood, RJ. Motivational deficits after brain injury: effects of bromocriptine in 11 patients. J Neurol Neurosurg Psychiatry. 1996;60:416–421.Google Scholar
89.Cooper, JR, Bloom, FE, Roth, RH. The Biochemical Basis of Neuropharmacology, 7th ed. New York, NY: Oxford University Press; 1996:194–225.Google Scholar
90.Papke, R. The kinetic properties of neuronal nicotinic acetylcholine receptors: genetic basis of functional diversity. Prog Neurobiol. 1993;41:509–531.Google Scholar
91.Sargent, PB. The diversity of neuronal nicotinic acetylcholine receptors. Br J Psychiatry. 1993;16:403–444.Google ScholarPubMed
92.Peters, BH, Levin, HS. Effects of physostigmine and lecithin on memory in Alzheimer's disease. Ann Neurol. 1979;6:219–221.Google Scholar
93.Muramoto, O, Sugishita, M, Sugita, H, Toykura, Y. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. Arch Neurol. 1979;36:501–503.Google Scholar
94.Thai, LJ, Fuld, PA, Masur, DM, Sharpless, NS. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol. 1983;13:491–496.Google Scholar
95.Thal, LJ, Masur, DM, Sharpless, NS, Fuld, PA, Davies, P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:627–636.Google Scholar
96.Davis, KL, Thal, LJ, Gamzu, ER, et al.A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992;327:1253–1259.Google Scholar
97.Rogers, SL, Friedhoff, LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996;7:293–303.Google Scholar
98.Rogers, SL, Doody, RS, Mohs, RC, Friedhoff, LT. Donepezil improves cognition and global function in Alzheimer's disease: a 15 week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021–1031.Google Scholar
99.Taverni, JP, Seliger, G, Lichtman, SW. Donepezil mediated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj. 1998;12:77–80.Google Scholar
100.Pomerleau, OF. Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacology. 1986;22:865–869.Google Scholar
101.Wesnes, K, Revell, A. The separate and combined effects of scopolamine and nicotine in human information processing. Psychopharmacology. 1984;84:5–11.Google Scholar
102.White, HK, Levin, ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (Berl). 1999;143:158–165.Google Scholar
103.Glennon, RA. Serotonin receptors: clinical implications. Neurosci Biobehav Rev. 1990;14:35–47.Google Scholar
104.Sleight, AJ, Pierce, PA, Schmidt, AW, et al.The clinical utility of serotonin receptor active agents in neuropsychiatric disease. In: Perontka, SJ, ed. Serotonin Receptor Subtypes. New York, NY: Wiley-Liss; 1991:211–227.Google Scholar
105.Kilpatrick, GJ, Bunce, KT, Tejers, MB. 5-HT3 receptors. Med Res Rev. 1990;10:441–475.Google Scholar
106.Zifa, E, Fillson, G. 5-Hydroxytryptamine receptors. Pharmacol Rev. 1992;44:401–458.Google Scholar
107.Chugh, Y, Saha, N, Sankaranayanan, A, Sharma, PL. Memory enhancing effects of granisetron (BRL 43694) in a passive avoidance task. Eur L Parmacol. 1991;203:121–123.Google Scholar
108.Pitsikas, N, Borsini, F. Itaseron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. Eur J Pharmacol. 1996;311:115–119.Google Scholar
109.Fontana, DJ, Daniels, SE, Eglen, RM, Wong, EH. Steroselective effects on (R) - and (S) zacopride on cognitive performance in a spatial navigation task in rats. Neuropharmacology. 1996;35:321–327.Google Scholar
110.Fontana, DJ, Daniels, SE, Wong, EH, Clark, RD, Eglen, RM. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigations. Neuropharmacology. 1997;36:689–696.Google Scholar
111.Meneses, A, Hong, E. Effects of 5-HT4 receptor agonists and antagonists in learning. Pharmacol Biochem Behav. 1997;56:347–351.Google Scholar
112.Kilpatrick, GJ, Hagan, RM, Gale, JD. 5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system. Behav Brain Res. 1996;73:11–13.Google Scholar
113.Deurwaerdere, P, L'hirondel, M, Bonhomine, N, Lucas, G, Cheramy, A, Spampinato, U. Serotonin stimulation of 5-HT4 receptors indirectly enhances in vivo dopamine release in the rat striatum. J Neurochem. 1997;68:195–203.Google Scholar
114.Tsai, SJ, Chiu, HJ, Wang, YC, Hong, CJ. Association study of serotonin - 6 receptor variant (C267T) with schizophrenia and aggressive behavior. Neurosci Lett. 1991;271:135–137.Google Scholar
115.Hamon, M, Doucet, E, Lefevre, K, et al.Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors. Neuropsychopharmocology. 1999;21(suppl):685–765.Google Scholar
116.Frederick, JA, Meodor-Woodruff, JH. Effects of clozapine and haloperiodol on 5-HT6 receptor mRNA levels in rat brain. Schizophr Res. 1999;38:7–12.Google Scholar
117.Glatt, CE, Snowman, AM, Sibley, DR, Snyder, SH. Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile. Mol Med. 1995;1:398–406.Google Scholar
118.Andersen, G, Vestcrgaard, K, Lauritzen, L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994;25:1099–1104.Google Scholar
119.Fullerton, AG. Side-effects of nortriptyline treatment for poststroke depression [letter]. Lancet. 1984;1:579.Google Scholar
120.Agerhohm, M. Side-effects of nortriptyline treatment for poststroke depression [letter]. Lancet. 1984;1:574.Google Scholar
121.Boyeson, MG, Harmon, RL. Effects of trazodone and desipramine on motor recovery in brain injured rats. Arch Phys Med Rehabil. 1992;73:994.Google Scholar
122.Boyeson, MG, Harmon, RL. Effects of trazodone and desipramine on motor recovery in brain-injured rats. Am J Phys Med Rehabil. 1993;72:286–293.Google Scholar
123.Patterson, DE, Braverman, SE, Belandres, PV. Speech dysfunction due to trazodone - fluoxetine combination in traumatic brain injury. Brain Inj. 1997;11:287–291.Google Scholar
124.Boyeson, MG, Harmon, RL, Jones, JL. Comparative effects of fluoxetine, amitryptyline and serotonin on functional motor recovery after sensorimotor cortex injury. Am J Phys Med Rehabil. 1994;73:76–83.Google Scholar
125.Dan, M, Tonin, P, Deboni, A, et al.Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211–1214.Google Scholar
126.Andersen, G, Vestergaard, K, Riis, JO. Citalopram for poststroke pathological crying. Lancet. 1993;342:837–839.Google Scholar
127.Ross, ED, Stewart, RS. Pathological display of affect in patients with depression and right frontal brain damage: an alternative mechanism. J Nerv Merit Dis. 1987;175:165–172.Google Scholar
128.Nahas, Z, Arlinghaus, KA, Kotrla, KJ, Clearman, RR, George, NS. Rapid responses of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci. 1998;10:453–455.Google Scholar
129.Tsai, WC, Lai, JS, Wang, TG. Treatment of emotionalism with fluoxetine during rehabilitation. Scand J Rehabil Med. 1998;30:145–149.Google Scholar
130.Andersen, G, Stylsing, M, Sunde, N. Citalopram treatment of traumatic brain damage in a 6-year-old boy. J Neurotrauma. 1999;16:341–344.Google Scholar
131.Seliges, GM, Hornstein, A, Flax, J, Herbert, J, Schroeder, K. Fluoxetine improves emotional incontinence. Brain Inj. 1992;6:267–270.Google Scholar
132.Andersen, G, Vestergaard, K, Riis, J. Citalopram for poststroke pathological crying. Lancet. 1993;342:837–839.Google Scholar
133.Gilman, S and Newman, SW. Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology, 9th ed. Philadelphia, PA: F.A. Davis Company; 1996:239,241,242,244.Google Scholar